We demonstrated that PRMT5-mediated meR316-ALKBH5 promotes CD276 messenger RNA (mRNA) stability through m6A modification, thereby enhancing CRC tumor immune evasion both in vitro and in vivo. The gene discussed is PRMT5; the disease is neoplasm.